Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity

Jean-Francois Rossi, Hao-Chun Chiang, Zhao-Yang Lu, Kalle Levon, Frits van Rhee, Karan Kanhai, David C Fajgenbaum, Bernard Klein

Blood (2021) 138 (Supplement 1): 4004.

https://doi.org/10.1182/blood-2021-150433

Published: 2021

Journal Articles

BNT162b2 mRNA COVID-19 Vaccination (BNTCV) in Patients (Pts) Having Hematological Malignancies (HM): Early tolerance with telemedicine application connecting and antibody anti-Spike IgG response (AcAS)

Jean-Francois Rossi, Emmanuel Bonnet, Marion Velensek, Emma Wisniewski, Sophie Heraud, Rania Boustany, Celeste David, Jerome Dinet, Roland Sicard, Jean Pierre Daures, Marion Bonifacy, Lysiane Mousset, Emmanuel Goffard

Blood (2021) 138 (Supplement 1): 1879.

https://doi.org/10.1182/blood-2021-154539

Published: 2021

Journal Articles

Apavac, a Simple Autologous Vaccination Process (AV) Associated with Clinical Efficacy in 56 Patients (pts) Having Cancer (C) and 11 Pts Having Hematological Malignancies (HM)

Jean-Francois Rossi, MD PhD, Nicole Rouquet, PhD, Patrick Frayssinet, MD PhD

Blood (2018) 132 (Supplement 1): 5690.

https://doi.org/10.1182/blood-2018-99-118862

Published: 2018

Journal Articles

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Blood (2018) 132 (20): 2115–2124.

https://doi.org/10.1182/blood-2018-07-862334

Published: 2018

Includes: Supplemental data

Journal Articles

International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

Blood (2017) 129 (12): 1646–1657.

https://doi.org/10.1182/blood-2016-10-746933

Published: 2017

Journal Articles

Controlled Epstein-Barr Virus Reactivation After Allogenic Transplantation Improves Survival and Is Associated To An Expansion Of Natural Killer Cells (NK)

Sophie Auger, MD, Mattea Orsini, Patrice Ceballos, MD, Nathalie Fegueux, MD, Bernard Klein, PhD, Martin Villalba, Jean-Francois Rossi, MD, PhD

Blood (2013) 122 (21): 4594.

https://doi.org/10.1182/blood.V122.21.4594.4594

Published: 2013

Journal Articles

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6

Blood (2013) 121 (22): 4493–4503.

https://doi.org/10.1182/blood-2012-05-429415

Published: 2013

Includes: Supplemental data

Journal Articles

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

Mathias Witzens-Harig, MD, Dirk Hose, MD, PhD, Simone Jünger, Christina Pfirschke, Nisit Khandelwal, Anja Seckinger, MD, Heinke Conrad, Bettina Brackertz, Thierry Reme, Brigittte Gückel, Tobias Meissner, Michael Hundemer, Anthony D Ho, MD, Jean-Francois Rossi, MD, PhD, Kai Neben, MD, Helga Bernhard, MD, Hartmut Goldschmidt, MD, Bernard Klein, Philipp Beckhove

Blood (2012) 120 (21): 2942.

https://doi.org/10.1182/blood.V120.21.2942.2942

Published: 2012

Journal Articles

Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT

Blood (2012) 120 (21): 1975.

https://doi.org/10.1182/blood.V120.21.1975.1975

Published: 2012

Journal Articles

Use of Rituximab As a Pre-Emptive Therapy for Epstein-Barr Virus (EBV)-Associated Lymphoproliferative Disorders in 86 Adult Patients Having Allogeneic Stem Cell Transplantation

Sophie Auger, MD, Mattea Orsini, Nathalie Fegueux, Patrice Ceballos, MD, Marie Luce Mines, Jean-Francois Rossi, MD, PhD

Blood (2011) 118 (21): 1995.

https://doi.org/10.1182/blood.V118.21.1995.1995

Published: 2011

Journal Articles

Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications

Verena Wagner, Dirk Hose, MD, Anja Seckinger, Ludmila Weitz, MSc, Tobias Meißner, Thierry Reme, Jean-Francois Rossi, MD, PhD, Hartmut Goldschmidt, MD, Alwin Krämer, MD, Bernard Klein, Marc S Raab, MD

Blood (2011) 118 (21): 137.

https://doi.org/10.1182/blood.V118.21.137.137

Published: 2011

Journal Articles

Malignant Plasma Cells Responsible for Multiple Myeloma Relapse Are Detectable and Survive Nine Days After High Dose Melphalan: Highlight of An Optimal Therapeutic Window ?

Anouk Caraux, PhD, Laure Vincent, Jerome Moreaux, PhD, Guilhem Requirand, Caroline Bret, PharmD, PhD, Jean-Luc Veyrune, PhD, Christophe Duperray, Salahedine Bouhya, MD, Jean-Francois Rossi, MD, PhD, Bernard Klein, PhD

Blood (2011) 118 (21): 131.

https://doi.org/10.1182/blood.V118.21.131.131

Published: 2011

Journal Articles

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Marc S Raab, MD, PhD, Thierry Facon, MD, Ravi Vij, MD, Philippe Moreau, MD, Donna E. Reece, MD, FRCPC, Darrell J. White, MD, Lotfi Benboubker, MD, PhD, Jeffrey A. Zonder, MD, Jean-Francois Rossi, MD, PhD, Claire Tsao, Teresa Parli, Glenn Kroog, MD, Anil K Singhal, Paul G. Richardson, MD

Blood (2011) 118 (21): 303.

https://doi.org/10.1182/blood.V118.21.303.303

Published: 2011

Journal Articles

Bortezomib Overcomes Usual Prognosis Factor in Patients with Multiple Myeloma (MM) Having High Dose Therapy (HDT)

Sophie Auger, MD, Philippe Quittet, MD, Salaheddine Bouhya, MD, Tarik Kanouni, MD, Pascal Latry, MD, Mattea Orsini, Jean-Francois Rossi, MD, PhD

Blood (2011) 118 (21): 3104.

https://doi.org/10.1182/blood.V118.21.3104.3104

Published: 2011

Journal Articles

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program

Blood (2011) 118 (16): 4338–4345.

https://doi.org/10.1182/blood-2011-03-340166

Published: 2011

Includes: Supplemental data

Journal Articles

Immunogenicity and Safety of One Dose of Influenza A H1N1v 2009 Adjuvanted Vaccine for Unpreviously Treated Patients with Binet-Stage A Chronic Lymphoid Leukaemia of B-Cell Type (B-CLL): Result of a Prospective Study Conducted In 9 French Centers by the Intergroupe Français GOELAMS/GFLLC-MW

Jean-Francois Rossi, MD, PhD, Bastien Caumes, Florence Cymbalista, MD, PhD, Odile Launay, MD, Anne Krivine, MD, PHD, Vincent Levy, MD, PhD, Pierre Feugier, MD, PhD, Stéphane Leprêtre, MD, Loic Ysebaert, MD, PhD, Caroline Dartigeas, MD, Philippe Colombat, MD, Didier Bouscary, MD, PhD, Tarik Kanouni, MD, Edouard Tuaillon, MD, PhD, Véronique Leblond

Blood (2010) 116 (21): 3600.

https://doi.org/10.1182/blood.V116.21.3600.3600

Published: 2010

Journal Articles

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Paul G. Richardson, MD, Philippe Moreau, MD, Andrzej J Jakubowiak, MD, PhD, Thierry Facon, MD, Sundar Jagannath, MD, Ravi Vij, MD, Donna E Reece, MD, Darrell J White, MD, Marc S Raab, MD, PhD, Lotfi Benboubker, MD, PhD, Jean-Francois Rossi, MD, PhD, Claire Tsao, PhD, John Fry, David Berman, MD, PhD, Anil K Singhal, MD, Sagar Lonial, MD

Blood (2010) 116 (21): 986.

https://doi.org/10.1182/blood.V116.21.986.986

Published: 2010

Journal Articles

Umbilical Cord Blood Transplantion In Relapsed Multiple Myeloma

Nathalie Fegueux, MD, Meniane Jean-Come, MD, Laure Vincent, Patrice Ceballos, MD, Tarik Kanouni, MD, Jean-Francois Eliaou, MD, PhD, Bernard Klein, PhD, Jean-Francois Rossi, MD, PhD

Blood (2010) 116 (21): 2374.

https://doi.org/10.1182/blood.V116.21.2374.2374

Published: 2010

Journal Articles

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Guy Laurent, MD, PhD, Sylvie Lafaye de Micheaux, MD, Philippe Solal-Celigny, MD, Pierre Soubeyran, MD, PhD, Vincent Delwail, Hervé Ghesquières, MD, Catherine Thieblemont, MD, Eric Jourdan, MD, PhD, Lucile Beautier, Fabien Audibert, Patrick Squiban, MD, Helene Sicard, PhD, Jean-Francois Rossi, MD, PhD

Blood (2009) 114 (22): 1649.

https://doi.org/10.1182/blood.V114.22.1649.1649

Published: 2009

Journal Articles

Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the “real-life” : Result of the French Experience in 72 Adults.

Blood (2009) 114 (22): 3519.

https://doi.org/10.1182/blood.V114.22.3519.3519

Published: 2009

NARROW

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity

BNT162b2 mRNA COVID-19 Vaccination (BNTCV) in Patients (Pts) Having Hematological Malignancies (HM): Early tolerance with telemedicine application connecting and antibody anti-Spike IgG response (AcAS)

Apavac, a Simple Autologous Vaccination Process (AV) Associated with Clinical Efficacy in 56 Patients (pts) Having Cancer (C) and 11 Pts Having Hematological Malignancies (HM)

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

Controlled Epstein-Barr Virus Reactivation After Allogenic Transplantation Improves Survival and Is Associated To An Expansion Of Natural Killer Cells (NK)

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT

Use of Rituximab As a Pre-Emptive Therapy for Epstein-Barr Virus (EBV)-Associated Lymphoproliferative Disorders in 86 Adult Patients Having Allogeneic Stem Cell Transplantation

Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications

Malignant Plasma Cells Responsible for Multiple Myeloma Relapse Are Detectable and Survive Nine Days After High Dose Melphalan: Highlight of An Optimal Therapeutic Window ?

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Bortezomib Overcomes Usual Prognosis Factor in Patients with Multiple Myeloma (MM) Having High Dose Therapy (HDT)

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program

Immunogenicity and Safety of One Dose of Influenza A H1N1v 2009 Adjuvanted Vaccine for Unpreviously Treated Patients with Binet-Stage A Chronic Lymphoid Leukaemia of B-Cell Type (B-CLL): Result of a Prospective Study Conducted In 9 French Centers by the Intergroupe Français GOELAMS/GFLLC-MW

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Umbilical Cord Blood Transplantion In Relapsed Multiple Myeloma

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the “real-life” : Result of the French Experience in 72 Adults.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only